Democrats May Have Untied Trump's Hands on Pharma
Mytheos Holt Nov 15, 2018 12:01 AM
The conventional wisdom coming out of the 2018 midterm
elections is that President Trump is likely to be aggressively
"checked" by the incoming Democratic House of Representatives.
And, to some extent, that is clearly true, in view of the
oncoming flood of investigations and possibly impeachment
hearings for Trump and others. If nothing else, such actions are
likely to prove a nuisance for the president, as well as a
potential quagmire that could slow down his administration's
actions on any number of fronts.
However, while Democrats are likely to try to tie Trump's hands
in any number of other areas, there is one area where their
election may actually give him more leeway to pursue his agenda.
I speak of Trump's potential battle with the pharmaceutical
industry.
Firstly, recall that President Trump is no fan of Big Pharma,
and hasn't been since he ran for president in the first place.
On the stump, candidate Trump accused the industry of "getting
away with murder." Nor are they fans of his - the industry
donated more to Hillary Clinton's presidential campaign than to
all other candidates. Since taking office, moreover, Trump has
struck an antagonistic note in dealing with the industry, and has
appointed officials - like Food and Drug Administration (FDA)
head Scott Gottlieb and Health and Human Services (HHS) Secretary
Alex Azar - who have committed to getting tough on Pharma. And
in many ways, they have, most notably via Trump and Azar's
decision to weaponize Medicare negotiations against the industry,
and via Trump's orders to now-retired Attorney General Jeff
Sessions to sue the industry for its role in the opioid crisis.
However, one major problem stood in the way of Trump's justified
fury against pharma: namely, that much of the Republican congress
remained in thrall to the industry, either through its money, or
through its attempt to frame its shameless monopolistic power
grabs as part of the free market (this is, by definition, false).
And, while Pharma has its share of defenders among Democrats
(including Cory "Spartacus" Booker), the recent elections proved
an ancient rule of politics true: namely, that politicians like
money a lot, but they like power more. Hence, the incoming
Democratic House caucus owes its position as much to its
campaigning against high drug prices and the opioid epidemic -
both products of Pharma's malfeasance - as it does to suburban
discontent with the president. Certainly, concerns over
healthcare were what kept otherwise deeply embattled Democratic
senators such as Joe Manchin (D-WV) and Jon Tester (R-MT) in
place. Small wonder that Senate Majority Leader Mitch McConnell
(R-KY) has suddenly also become very interested in reining in
drug prices.
That this represents a problem for Pharma is obvious. And the
industry knows it. In one of the more satisfying stories to
emerge since the election, the Washington Examiner has noted that
the potential for a Pelosi-Trump-McConnell alliance on tackling
drug prices has the industry "sweating bullets" and suddenly
finding that all their money and influence has vanished in the
Capitol, now that everyone realizes that siding with the industry
can make the difference between election and failure. Given that
Washington, until recently, abided by the catchphrase "Pharma
always wins," this is a welcome reversal for those who want a
drug policy that works for the normal Americans that make up
Trump's base, rather than the donor class.
Let's be clear: if Pelosi, Trump, and McConnell can hammer out
legislation that addresses the high drug pricing and opioid
epidemics, it will mark one of the most consequential
achievements for all three people. Indeed, it may be that these
problems can only be solved by an eclectic mix of leaders such as
those three. It's too soon to say what such legislation would
look like, but one suspects a combination of genuine free market
remedies such as opening up the market for generic drugs and
cracking down on drug company patent abuse, as well as previously
liberal ideas such as Medicare negotiating prices, could all be
involved.
In short, yes, President Trump may face a bench of political
opponents that are empowered, but those people share an enemy
with him who arguably did more to get them elected than he did.
And older than the adage that Pharma always wins is a much more
comforting line: the enemy of my enemy is my friend.